Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Arsanis
890 Winter Street, Suite 230
Waltham, MA 02451
http://arsanis.com/

Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company's current programs address pathogenic processes selectively, rather than aiming to broadly eliminate pathogens, potentially allowing Arsanis to address critical infections without contributing to the problem of antimicrobial resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is being evaluated in a Phase 2 clinical study for the prevention of Staphylococcus aureus pneumonia in high-risk patients.

Key Contact
Name
Rene Russo
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
04/26/17 $45,500,000 Series D Alexandria Real Estate Equities
Bill & Melinda Gates Foundation
EMBL Ventures
NeoMed Management
OrbiMed Advisors
Polaris Partners
Stephen Kellen Foundation
SV Health Investors
undisclosed